Frameworks for Digital Advertising
Standards in Medicine.

United States · Advertising framework

Search advertising for prescription medicines in the United States

General market orientation, not campaign clearance. Research scope and dates

Product and service rules

US consumer prescription-drug advertising is a conditional route

Legal requirement — paraphrased

Federal rules permit consumer prescription-drug advertisements subject to detailed requirements. Product-claim ads must present supported approved uses and appropriately balanced effectiveness and risk information. Reminder exemptions have strict limits, including restrictions for boxed-warning products. This is not a general permission to advertise an unapproved product or use.

Sources: 21 CFR 202.1 — Prescription-drug advertisements

Channel rules

Apply the FDA prescription-advertising standard

Legal requirement — paraphrased

Prescription-drug advertising follows the FDA framework, including misleading-presentation and fair-balance requirements under 21 CFR 202.1. Review the prominence of benefits and risks and the information required for the execution. General FTC health-product guidance is not a substitute for the FDA prescription-drug advertising rules.

Sources: 21 CFR 202.1 — Prescription-drug advertisements

Washington health data may be regulated outside HIPAA

Regulator guidance

Applies when: Processing within the scope of Washington’s My Health My Data Act.

Where Washington’s My Health My Data Act applies, collection generally needs purpose-specific consent unless necessary for a requested product or service; sharing requires a distinct consent unless the necessary-service exception applies. Review applicability and exemptions by data and activity, rather than assuming HIPAA status clears advertising tracking. Regulated entities must prominently link a separate consumer health data privacy policy from the homepage.

Sources: Washington consumer-health-data collection and sharing; My Health My Data Act — scope and FAQ

Control short copy and dynamic assets

Editorial recommendation

Approve keywords, responsive assets, sitelinks and destinations together. Disable combinations that would lose a required qualification. A landing page is not an automatic substitute for information required in the ad itself.

Campaign workflow

Prescription Medicines: prepare the review

Editorial recommendation

Identify the exact authorised medicine and prescription status. Resolve the public-promotion restriction or permitted route before developing creative. Separate medicine promotion from neutral disease information and healthcare-service advertising.

Keep a traceable campaign decision

Editorial recommendation

Keep one review record linking the offer, local market status, claim evidence, exact creative, media settings and any regulatory or professional clearance. Record who checked each condition. Reopen the review when the offer, claim, source rule or execution changes.

Pre-publication checklist

  • Identify the exact authorised medicine and prescription status.
  • Resolve the public-promotion restriction or permitted route before developing creative.
  • Separate medicine promotion from neutral disease information and healthcare-service advertising.
  • Record product or provider eligibility before approving claims.
  • Archive the final creative and its evidence, permissions and review decisions.
  • Assign an owner for source updates, complaints and prompt withdrawal of inaccurate material.

Scope and unresolved questions

  • California physician telehealth and Washington consumer-health-data requirements are now documented as scoped examples. Other state medical/dental/pharmacy rules, corporate practice, fee splitting, referral arrangements and state telemarketing laws remain to be assessed for the actual provider and patient location.
  • FDA television/radio-format standards and a scoped Washington health-data rule are documented. Exact TCPA revocation implementation dates and post-litigation consent text were not fully verified from accessible primary documents; final SMS clearance remains open. Platform, broadcaster and other state rules depend on the actual execution.
Research scope, introduction and dates

Prescription-medicine advertising in search ads in the United States starts with a legal eligibility decision. Establish whether the proposed consumer message is permitted, restricted to limited information or confined to a professional route before developing benefit and risk statements.

Search advertisements leave little space for qualifications. Review the visible copy, extensions and dynamic assets together with the destination, and establish whether the format can carry the information the advertisement requires.

Sources checked 2026-10-24 · Editorial research · Legal review pending

General market orientation, not legal, regulatory or medical advice, a complete compliance plan or clearance of an advertisement. Actual requirements depend on the specific offer and campaign.

Coverage: National baseline and category-specific review routes; not an exhaustive compliance opinion

How to use this national baseline

Editorial overview

This framework combines researched national rules with editorial review steps. Federal advertising baseline; state professional, pharmacy and privacy rules require a separate review. A visible channel workflow does not establish that the selected product or service may be advertised there. Read the category restrictions first.

The review date identifies when the cited provisions or regulator excerpts were checked. It does not mean that every local rule, exception, professional standard or platform policy has been reviewed.

Your next step: choose a local partner

Use this framework to brief qualified local legal and regulatory specialists. Ask them to verify current requirements and assess your specific product, service and campaign before acting.

Sources

  1. 21 CFR 202.1 — Prescription-drug advertisements

    FDA / eCFR · legislation · checked 2026-10-24

    Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.

  2. My Health My Data Act — scope and FAQ

    Washington Attorney General · regulator guidance · checked 2026-10-25

    Follow-up review of the cited issue on 25 October 2026; scope and remaining conditions are recorded in the modules and review register.

From framework to action

Local expertise in United States

Find support with medical and health marketing, marketing and sales advice, or organizing your business and coordinating projects in United States.

Medical & health marketing

No partners listed in this category yet.

Marketing & sales advisory

No partners listed in this category yet.

Business & project coordination

No partners listed in this category yet.

Browse partners in United States

Join the local partner directory

Would you like your company to be listed?

Talk to us about the terms of a listing. Leave your details and we will get in touch.

Publicity@fdasm.com

Contact details for a partner listing enquiry

We use your details to respond to your enquiry and discuss a listing. Submitting the form does not automatically add your company to the directory. Read our Privacy & cookies policy. Privacy contact: Publicity@fdasm.com.